当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Helen Cribb
Organ transplantation has become a common practice in modern medicine. With advancements in surgical techniques and immunosuppressive therapies, the success rates of organ transplantation have significantly increased, providing patients with a new lease of life. However, transplantation is not without its challenges. The immune system of recipients recognizes transplanted organs as foreign, triggering an immune response that can lead to graft rejection. This process is mediated by various immune cells and molecules, including T cells, B cells, antibodies, cytokines, and complement proteins. To prevent graft rejection, patients receive immunosuppressive drugs that suppress their immune system, but these drugs have side effects and can increase the risk of infections and cancer. Therefore, there is a need for alternative strategies to induce transplantation tolerance, which refers to the state of immune unresponsiveness towards the transplanted organ. Transplantation tolerance can eliminate or reduce the need for immunosuppressive drugs and improve the long-term outcomes of transplantation. In this article, we will review the current understanding of transplantation tolerance and the strategies that are being developed to achieve it.